Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegcetacoplan - Apellis Pharmaceuticals/Swedish Orphan Biovitrum

Next Previous
X
Search
Drug Profile

Pegcetacoplan - Apellis Pharmaceuticals/Swedish Orphan Biovitrum

Alternative Names: APL-2; Aspaveli; EMPAVELI; Pegcetacoplan injection - Apellis Pharmaceuticals/Swedish Orphan Biovitrum; SYFOVRE

Latest Information Update: 13 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Apellis Pharmaceuticals
  • Developer Apellis Pharmaceuticals; Swedish Orphan Biovitrum
  • Class Anti-inflammatories; Anti-ischaemics; Antianaemics; Antithrombotics; Cyclic peptides; Eye disorder therapies; Polyethylene glycols; Urologics
  • Mechanism of Action Complement C3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Autoimmune haemolytic anaemia; Paroxysmal nocturnal haemoglobinuria; Glomerulonephritis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Age-related macular degeneration; Paroxysmal nocturnal haemoglobinuria
  • Phase III Membranoproliferative glomerulonephritis
  • Phase II Glomerulonephritis; IgA nephropathy; Lupus nephritis; Membranous glomerulonephritis; Thrombotic microangiopathy
  • Phase I/II Wet age-related macular degeneration
  • Discontinued Amyotrophic lateral sclerosis; Autoimmune haemolytic anaemia; Ischaemia

Most Recent Events

  • 08 Aug 2024 Apellis Pharmaceuticals announces intention to submit sNDA to US FDA for Membranoproliferative glomerulonephritis (SC, Injection) in early 2025
  • 08 Aug 2024 Swedish Orphan Biovitrum announces intention to submit MAA to EMA for Membranoproliferative glomerulonephritis (SC, Injection) in 2025
  • 08 Aug 2024 Efficacy and adverse events data from the phase III VALIANT trial in Membranoproliferative glomerulonephritis released by Apellis Pharmaceuticals

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top